AlloVir Revenue and Competitors

Boston, MA USA

Location

$159M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • AlloVir's estimated annual revenue is currently $22.6M per year.(i)
  • AlloVir's estimated revenue per employee is $174,077
  • AlloVir's total funding is $159M.
  • AlloVir's current valuation is $677.5M. (January 2022)

Employee Data

  • AlloVir has 130 Employees.(i)
  • AlloVir grew their employee count by -4% last year.

AlloVir's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
SVP Business DevelopmentReveal Email/Phone
3
SVP, Global Regulatory AffairsReveal Email/Phone
4
VP - Quality OperationsReveal Email/Phone
5
Head Clinical Data ManagementReveal Email/Phone
6
SVP, Corporate LawReveal Email/Phone
7
VP, Head ITReveal Email/Phone
8
VP, BiometricsReveal Email/Phone
9
Head Quality and Compliance, GCP/GVP and RegulatoryReveal Email/Phone
10
SVP, Development Strategy & OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is AlloVir?

AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The companyᅢᄁ¬ツᆲ¬トᄁs technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. AlloVirᅢᄁ¬ツᆲ¬トᄁs technology and manufacturing process enables the potential for the treatment and/or prevention of up to six devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.

keywords:N/A

$159M

Total Funding

130

Number of Employees

$22.6M

Revenue (est)

-4%

Employee Growth %

$677.5M

Valuation

N/A

Accelerator

AlloVir News

2022-04-20 - FDA Grants Regenerative Medicine Advanced Therapy ...

AlloVir's lead product, posoleucel, is in late-stage clinical development as an allogeneic, off-the-shelf, multi-virus specific T cell...

2022-04-20 - AlloVir Snags Coveted RMAT Designation For T Cell Therapy

AlloVir, a late clinical-stage allogeneic T cell immunotherapy company, announced Wednesday that it has received an FDA RMAT designation for...

2022-04-20 - AlloVir Up After FDA Grants Regenerative Medicine Advanced Therapy Designation ALVR

AlloVir Inc. shares rose 21% to $6.53 premarket after the company said the U.S. Food and Drug Administration granted regenerative medicine...

2021-03-22 - AlloVir Appoints Diana M. Brainard, M.D., as Chief Executive Officer, Effective May 17, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 22, 2021-- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced today that its Board of Directors has appointed Diana M. Brainard, M.D., as the company’s Chief Executive Officer (CEO), effective May 17, 2021. Dr. Brainard has serve ...

2019-05-22 - ElevateBio names AlloVir as its first portfolio company

Based in Houston, AlloVir is developing allogeneic cell therapies for viral diseases and is planning Phase III studies for its lead product candidate, Viralym-M, within the next 12 months. The cell therapy is being developed for six viruses commonly found in patients with compromised immune syst ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$16.9M130-8%$119.7M
#2
$45.9M13069%N/A
#3
$31.8M131-3%$10.8M
#4
$13.4M13110%N/A
#5
$7.5M131-13%N/A